DMG-PEG 2000, also called 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000, is used for liposome preparation. DMG-PEG 2000 has become known for lipid nanoparticle (LNP) preparation for siRNA (small interfering RNA) delivery in the COVID-19 vaccine development. DMG-PEG 2000 has been used in studies for anticancer drug delivery studies for hepatocellular, gastrointestinal, neuroendocrine and adrenocortical carcinoma.
DMG-PEG2000 is used for the preparation of liposomes for siRNA delivery, which can improve the transfection efficiency. It can also be used for the preparation of lipid nanoparticles for in vivo delivery of orally administered plasmid DNA. DMG-PEG2000 can improve the mucus permeability and delivery efficiency of nanoparticles.
DMG-PEG 2000 is soluble in ethanol, DMSO and chloroform:methanol (9:1) at a concentration of 5 mg/mL; store at -20°C. Generally transported on dry ice.
DMG-PEG 2000 is a lipid excipient that has been used in combination with other lipids to form lipid nanoparticles (LNPs) for delivery of COVID-19 mRNA vaccines.
NP-3 (0.05-1.6 mg/mL; 24 hours) does not decrease the cytotoxicity of cells in 293T, HepG2, A549, and HeLa cell lines, but the DPPC and DMG-PEG coated nanoparticles reduce cell cytotoxicity. In addition, the transfection efficiency of DPPC/DMG-PEG/(lPEI/DNA) nanoparticles (NP-3) in 293 cells is improved, and the maximum transfection efficiency (～76% eGFP positive cells) is observed.
NP-3 (oral administration; 150 μg DNA per mouse; single dose) at 12, 24, and 36 h postadministration, luciferin substrate is intraperitoneally injected to verify its permeability. NP-3 group maintains high luciferase expression in the liver, lung, and intestine areas 12-24 h post-treatment.Additionally, NP-3 exhibits 1.5 times higher signal intensity than that of NP-1 or NP-2 group from 12 to 24 h postoral administration.
